Longboard Pharmaceuticals Inc
San Diego, CA
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
longboardpharma.comCompany Details
Founded
- 2020
Employees
- Between 10 - 50 employees
Raised
- $1,596,968
Headquarters Location
- San Diego, CA
Public
- Yes
Acquired
- Yes
Founders
- Bassam Damaj
Company Collections
These are collections Longboard Pharmaceuticals Inc is a part of. Click on the collection name to view similar companies.
Longboard Pharmaceuticals Inc's Industries
Longboard Pharmaceuticals Inc Headquarters Location
Total Amount Raised: $1,596,968
Longboard Pharmaceuticals Inc Funding Rounds
Post Ipo Equity
$1,072,300
Post Ipo Debt
$350,000
Post Ipo Debt
$174,668
IPO
Unknown
Longboard Pharmaceuticals Inc Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Longboard Pharmaceuticals Inc.